Evidence map›Paper›PMID 39427265›Full record

Trial reportIntegrative cancer therapies

Clinical Efficacy of Hexue Tongbi Formula on Oxaliplatin-Induced Peripheral Neuropathy: A Randomized Controlled Study.

Lingling Sun, Yiying Lv, Duo Li, Jingyu Feng, Zhuangzhong Chen, Lizhu Lin

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lingling SunGuangzhou University of Chinese Medicine, Guangzhou, China.ORCID 0009-0006-0991-672X
Yiying LvGuangzhou University of Chinese Medicine, Guangzhou, China.
Duo LiGuangzhou University of Chinese Medicine, Guangzhou, China.
Jingyu FengGuangzhou University of Chinese Medicine, Guangzhou, China.
Zhuangzhong ChenGuangzhou University of Chinese Medicine, Guangzhou, China.
Lizhu LinGuangzhou University of Chinese Medicine, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe aim of this study was to analyse the effiacy of HeXue Tongbi Formula in the treatment of oxaliplatin-induced perpheral neuropathy.

methodAn open randomized, non-blind, controlled study was conducted at the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine from September 2019 to December 2020. A total of 78 maligant tumor patients receiving oxaliplatin-containing chemotherapy were recruited, with half of them receiving HeXue Tongbi Formula for 4 cycles of 21 days. The study assessed the incidence and severity of perpheral neuropathy and the safety of HeXue Tongbi Formula.

resultAfter 4 cycles of treatment, the incidence of perpheral neuropathy in the treatment group was significantly lower than that in the control group (30.77% versus 84.62%,

conclusionHeXue Tongbi Formula demonstrated good preventive and therapeutic effects on oxaliplatin-induced perpheral neuropathy.

trial registrationThis trial has been registered with the Chinese Clinical Trial Registry (ChiCTR2000032996).

Indexed as

Drugs, Chinese HerbalOxaliplatinPeripheral Nervous System DiseasesAdultAgedAntineoplastic AgentsFemaleHumansMaleMedicine, Chinese TraditionalMiddle AgedAntineoplastic AgentsDrugs, Chinese HerbalOxaliplatinchemotherapy-induced side effectsChinese herbal medineHeXue Tongbi formulaoxaliplatin-induced peripheral neuropathyrandomized controlled trial

Identifiers

PMID39427265
PMCPMC11503713

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.